SCHEMBL7270893

SCHEMBL7270893

CCCc1[nH]c(=O)oc1-c1ccnc(-c2ccccc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPKAPK2 P49137 2/20 0.40
CDK1 P06493 1/20 0.40
MAPKAPK3 Q16644 1/20 0.40
MAPKAPK5 Q8IW41 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
SREBF2 Q12772 1/20 0.39
PIM1 P11309 1/20 0.39
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
PDE5A O76074 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ASIC3 Q9UHC3 1/20 0.36
TGFBR1 P36897 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8846 0.77 PDE3B (0.46) PDE3BPDE3ASMN1; SMN2ADORA1KDM4E
SCHEMBL9361685 0.73 PDE10A (0.44) ELANE
SCHEMBL7437589 0.72 PDE3B (0.39) PDE3BPDE3AADORA1HPGD
SCHEMBL9360794 0.67 ELANE (0.40) CYP1A2CYP3A4CYP2C9CYP2C19ELANE
SCHEMBL21692157 0.66 ASIC3 (0.65) MAPKAPK2CDK1MAPKAPK3MAPKAPK5MKNK1
SCHEMBL9365338 0.66 PARP1 (0.43) SMN1; SMN2TGFBR1ELANEKDM4ENPC1
SCHEMBL7272043 0.66 PDE3B (0.43) CYP1A2PDE3BPDE3ACYP2C19TGFBR1
SCHEMBL29578028 0.65 ASIC3 (0.63) MAPKAPK2CDK1MAPKAPK3MAPKAPK5MKNK1
SCHEMBL912763 0.65 ASIC3 (0.63) MAPKAPK2CDK1MAPKAPK3MAPKAPK5MKNK1
SCHEMBL9360294 0.64 NPC1 (0.49) CYP1A2CYP3A4SMN1; SMN2CYP2C19TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0539575-B1 INHIBITION OF METASTASIS IN PATIENTS HAVING CANCER WITH PYRIDYLOXAZOLE-2-ONES MERRELL PHARMA INC (US) 1997-07-23 EP disclosed
US-5610171-A Inhibition of metastasis in patients having cancer with pyridyloxazole-2-ones MERRELL PHARMACEUTICALS INC. (US) 1997-03-11 US disclosed
EP-0539575-A1 INHIBITION OF METASTASIS IN PATIENTS HAVING CANCER WITH PYRIDYLOXAZOLE-2-ONES. MERRELL DOW PHARMA (US) 1993-05-05 EP disclosed
US-5182293-A Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1993-01-26 US disclosed
WO-1992020337-A2 INHIBITION OF METASTASIS IN PATIENTS HAVING CANCER WITH PYRIDYLOXAZOLE-2-ONES MERRELL DOW PHARMACEUTICALS INC. (US) 1992-11-26 WO disclosed
US-5063238-A Kinase inhibitor MERRELL DOW PHARMACEUTICALS INC. (US) 1991-11-05 US disclosed
EP-0428103-A2 Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1991-05-22 EP disclosed
EP-0428104-A2 Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones MERRELL DOW PHARMACEUTICALS INC. (US) 1991-05-22 EP disclosed
EP-0428106-A1 Novel pyridyloxazole 2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1991-05-22 EP disclosed